UR
MRNA icon

USCA RIA’s Moderna MRNA Stock Holding History

USCA RIA’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,375
Closed -$704K – 581
2021
Q1 		$704K Buy
+5,375
New +$779K 0.05% 334

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

USCA RIA's MRNA Position: Q2 2021 in Review

USCA RIA sold out of Moderna (MRNA) in Q2 2021, closing a stake of 5,375 shares — an estimated $704K sold.

USCA RIA first reported a position in MRNA in Q1 2021 and held it in 1 quarter. The position peaked at $704K in Q1 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q2 2021.

  • USCA RIA reported no remaining Moderna position as of Q2 2021 after selling out during the quarter.
  • USCA RIA sold 5,375 Moderna shares in Q2 2021, an estimated $704K.
  • USCA RIA first reported a position in Moderna in Q1 2021 and held it in 1 quarter.
  • USCA RIA's Moderna position peaked at $704K in Q1 2021.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q2 2021.

Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.